Re­call re­port: Pfiz­er puts a stop on Chan­tix dis­tri­b­u­tion af­ter traces of pos­si­ble car­cino­gens found

Af­ter find­ing el­e­vat­ed lev­els of can­cer-caus­ing ni­trosamines, Pifz­er is halt­ing dis­tri­b­u­tion of its an­ti-smok­ing med Chan­tix and re­call­ing four lots of the drug.

This comes a year af­ter the FDA found high lev­els of ND­MA, a com­mon ni­trosamine, in some ver­sions of met­formin, a pop­u­lar gener­ic di­a­betes drug. Just last week, Viona Phar­ma­ceu­ti­cals is­sued a re­call for two lots of its 750 mg ex­tend­ed-re­lease met­formin tablets due to the pres­ence of ND­MA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER